EN DE
Watch Vanda Pharmaceuticals Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vanda Pharmaceuticals Inc (VNDA) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Vanda Pharmaceuticals Inc stock $4.06, price $4.09, that is 0.7% below the price, quality 42 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

VP Vanda Pharmaceuticals Inc logo Thin data Nov 10, 2026

Vanda Pharmaceuticals Inc

VNDA · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value $4.06 · Fairly valued
Quality 42/100
Mixed vs. peers (5/11)
Insiders bought $38,094 (6M)
Weak Growth (revenue 5y −2.7 %/yr in USD)
Loss-making · -127.4% net margin (TTM)
Negative free cash flow
Narrow moat 10/100 · thin data
Downbeat coverage
Thin data
Estimate
Watch Vanda Pharmaceuticals Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$21.14 $3.38 Fair Value $4.06 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $3.38 – $21.14 · fair‑value band $3.05 – $5.08 · the $4.09 price screens above the $4.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 5 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 10, 2026.

Follow Vanda Pharmaceuticals in your weekly email

Every Wednesday you see whether Vanda Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide.

Show moreShow less

The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion.

It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis.

In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders.

Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Stock analysis

Vanda Pharmaceuticals Inc (VNDA) currently trades at $4.09, while our estimate is $4.06, so the stock looks roughly fairly valued today (gap 0.7%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $3.05 (bear) to $5.08 (bull), the price of $4.09 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Vanda Pharmaceuticals Inc reported revenue of $216M in FY2025 versus $269M in FY2021, a compound −5.3%/yr. Reported net income was −$220M in FY2025.

Key figures

Market cap $246M Micro · P/S ratio 1.12 · EPS (TTM) $−4.63 · Net margin −127% · Return on equity −77.8% · Return on assets (EBIT) −6.2% (5-year average) · Operating margin −126% · Revenue (TTM) $216M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 57% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −6% fair-value upside, at −1%, VNDA screens cheaper than that median.

Fair Value

Bear $3.05 Fair Value $4.06 Bull $5.08
Price $4.09 · Downside -0.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 42/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 20
How much profit the company makes from its sales and capital
Quality Growth 39
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 43
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 17
Distance to the 52-week high, does not count
New shares 63
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $38,094, on Nov 5, 2026.

  • BuyCharles Cliff DuncanDirector10,000 shares at $3.81$38,094Nov 5, 2026
  • SaleMihael Hristos PolymeropoulosPresident and CEO, Director156,235 shares at $8.17$1.3MMar 2, 2026
  • SaleGunther BirznieksSVP, Business Development42,431 shares at $8.27$350,904Mar 2, 2026
  • SaleTimothy WilliamsSVP & General Counsel42,434 shares at $8.27$350,929Mar 2, 2026
  • SaleJoakim WijkstromSVP, Chief Marketing Officer30,800 shares at $8.27$254,716Mar 2, 2026
  • SaleKevin Patrick MoranSVP, CFO & Treasurer42,442 shares at $8.27$350,995Mar 2, 2026
  • SaleTage HonoreDirector30,000 shares at $8.03$240,900Feb 23, 2026

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 9, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+8.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.7%
Start year 2020 (pandemic). Over 10 years: +7.0% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+51.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
11.0% (2020) → −70.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch VNDA, get fair value alerts →

Earlier news

News mood ⓘNews mood, the average tone of recent news (95 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Vanda Pharmaceuticals Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 867 stocks

Beats the industry median on 4/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 42 · Above median
Fair Value upside −0.7% · Top 25%
Profitability
Return on assets −45.1% · Below median
Net margin (12 months) −127.4% · Bottom 25%
Operating margin (12 months) −126.3% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −3.9% · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.75× · Cheapest 25%
P/S (12 months) 1.14× · Cheapest 25%
PEG 2.23× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)32 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 19

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $919.96 $1,275 +39% vs VNDA
Samsung Biologics Co 207940 1,510,000 KRW 1,661,000 KRW +10% vs VNDA
Vertex Pharmaceuticals Incorporated VRTX $550.87 $601.80 +9% vs VNDA
Genmab A/S GMAB kr 3,661 kr 3,880 +6% vs VNDA
argenx SE ARGX $962.27 $908.40 −6% vs VNDA
CSL Limited CSL A$200.73 A$181.40 −10% vs VNDA
BeOne Medicines AG 6160 HK$248.20 HK$152.80 −38% vs VNDA
Roivant Sciences Ltd ROIV $40.67 $17.39 −57% vs VNDA
Celltrion, Inc 068270 210,000 KRW 74,945 KRW −64% vs VNDA
Royalty Pharma plc RPRX $68.77 $19.01 −72% vs VNDA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vanda Pharmaceuticals Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vanda Pharmaceuticals Inc Fair Value". https://www.fairvalue-calculator.com/stock/VNDA

Frequently asked questions

Is Vanda Pharmaceuticals Inc (VNDA) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $4.06 versus a price of $4.09, about 1% lower (fairly valued).
What is the fair value of VNDA?
Our estimate for Vanda Pharmaceuticals Inc is $4.06 (as of Nov 10, 2026), built from audited fundamentals. The current price: $4.09.
What is the quality score of VNDA?
Vanda Pharmaceuticals Inc has a Quality Score of 42/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vanda Pharmaceuticals Inc (VNDA)?
Our calculated price target is the estimate of $4.06 (as of Nov 10, 2026). Cautious scenario $3.05, optimistic scenario $5.08. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Vanda Pharmaceuticals Inc stock forecast for 2026?
Our estimate puts fair value at $4.06, about 1% lower versus a price of $4.09 (fairly valued). Cautious scenario $3.05, optimistic scenario $5.08. The calculation is refreshed regularly with new filings.
What is the revenue of Vanda Pharmaceuticals Inc (VNDA)?
Vanda Pharmaceuticals Inc reported trailing-twelve-month revenue of about $216M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Vanda Pharmaceuticals Inc (VNDA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vanda Pharmaceuticals Inc it is $4.06 per share (as of Nov 10, 2026), against a price of $4.09.
Is Vanda Pharmaceuticals Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, VNDA trades above its calculated fair value: price $4.09, fair value $4.06, a gap of about −1% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of VNDA?
No. The price is what the market pays today ($4.09); the fair value is what the company's own numbers justify ($4.06). For Vanda Pharmaceuticals Inc the two are $0.0300 per share apart. That gap is exactly why we show both numbers side by side.
How much is Vanda Pharmaceuticals Inc worth?
The market values Vanda Pharmaceuticals Inc at about $246M (market capitalisation, as of Nov 10, 2026). Per share that is $4.09; our models calculate a fair value of $4.06 per share.
What do the bullish and bearish scenarios say about VNDA?
Our models span a range for Vanda Pharmaceuticals Inc: cautious scenario $3.05, base $4.06, optimistic $5.08 per share (as of Nov 10, 2026, price $4.09). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of VNDA?
The PEG ratio of Vanda Pharmaceuticals Inc is 2.23 (P/E divided by earnings growth, as of Nov 10, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Vanda Pharmaceuticals Inc (VNDA)?
Balance-sheet figures for Vanda Pharmaceuticals Inc (as of Nov 10, 2026): return on equity −77.8%. They feed the Quality Score of 42/100, which measures business quality independently of the share price.
How far is VNDA from its 52-week high?
Vanda Pharmaceuticals Inc trades at $4.09, about 57% below its 52-week high of $9.56 and 14% above the low of $3.59 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of $4.06 is for.
Which stocks are comparable to Vanda Pharmaceuticals Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vanda Pharmaceuticals Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $4.09, calculated fair value $4.06 (−1%), Quality Score 42/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Vanda Pharmaceuticals Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vanda Pharmaceuticals Inc (VNDA)?
The closing price on Nov 9, 2026 was $4.09. Our estimate is $4.06, about 1% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vanda Pharmaceuticals Inc right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Vanda Pharmaceuticals Inc

How large is the market capitalisation of Vanda Pharmaceuticals Inc (VNDA)?
The market capitalisation of Vanda Pharmaceuticals Inc is $246M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Vanda Pharmaceuticals Inc (VNDA)?
The price-to-sales ratio of Vanda Pharmaceuticals Inc is 1.12 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Vanda Pharmaceuticals Inc (VNDA)?
Earnings per share at Vanda Pharmaceuticals Inc are $−4.63. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Vanda Pharmaceuticals Inc (VNDA)?
The net margin of Vanda Pharmaceuticals Inc is −127% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Vanda Pharmaceuticals Inc (VNDA)?
The return on equity (ROE) of Vanda Pharmaceuticals Inc is −77.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vanda Pharmaceuticals Inc (VNDA)?
On an EBIT basis the return on assets of Vanda Pharmaceuticals Inc is −6.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vanda Pharmaceuticals Inc (VNDA)?
The operating margin of Vanda Pharmaceuticals Inc is −126% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Vanda Pharmaceuticals Inc (VNDA)?
Revenue at Vanda Pharmaceuticals Inc is growing −3.9% versus a year earlier (3y avg −5.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Vanda Pharmaceuticals Inc (VNDA)?
Earnings per share at Vanda Pharmaceuticals Inc are growing −95.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Vanda Pharmaceuticals Inc (VNDA) generate?
The free cash flow of Vanda Pharmaceuticals Inc is −$110M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Vanda Pharmaceuticals Inc (VNDA) hold?
Vanda Pharmaceuticals Inc holds more cash than debt, $72.2M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Vanda Pharmaceuticals Inc in the live analysis

One click puts Vanda Pharmaceuticals Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.